EP4704877A2 - Modulation optogénétique par opsines à caractéristiques multiples pour la restauration de la vision et d'autres applications associées - Google Patents

Modulation optogénétique par opsines à caractéristiques multiples pour la restauration de la vision et d'autres applications associées

Info

Publication number
EP4704877A2
EP4704877A2 EP24797864.6A EP24797864A EP4704877A2 EP 4704877 A2 EP4704877 A2 EP 4704877A2 EP 24797864 A EP24797864 A EP 24797864A EP 4704877 A2 EP4704877 A2 EP 4704877A2
Authority
EP
European Patent Office
Prior art keywords
emco1
light
retinal
mice
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24797864.6A
Other languages
German (de)
English (en)
Inventor
Samarendra Kumar Mohanty
Sulagna BHATTACHARYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanoscope Therapeutics Inc
Original Assignee
Nanoscope Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanoscope Therapeutics Inc filed Critical Nanoscope Therapeutics Inc
Publication of EP4704877A2 publication Critical patent/EP4704877A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Selon un aspect, la présente invention concerne de manière générale des compositions et des procédés de modulation d'activités cellulaires par opsines synthétiques. En outre, l'invention concerne un procédé d'utilisation d'opsines synthétiques pour la restauration de la vision et d'autres applications, la séquence d'acides aminés de l'opsine synthétique étant modifiée pour fournir une sensibilité à la lumière, une cinétique et une sélectivité ionique améliorées.
EP24797864.6A 2023-04-24 2024-04-24 Modulation optogénétique par opsines à caractéristiques multiples pour la restauration de la vision et d'autres applications associées Pending EP4704877A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363461546P 2023-04-24 2023-04-24
PCT/US2024/026082 WO2024226667A2 (fr) 2023-04-24 2024-04-24 Modulation optogénétique par opsines à caractéristiques multiples pour la restauration de la vision et d'autres applications associées

Publications (1)

Publication Number Publication Date
EP4704877A2 true EP4704877A2 (fr) 2026-03-11

Family

ID=93257469

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24797864.6A Pending EP4704877A2 (fr) 2023-04-24 2024-04-24 Modulation optogénétique par opsines à caractéristiques multiples pour la restauration de la vision et d'autres applications associées

Country Status (3)

Country Link
EP (1) EP4704877A2 (fr)
JP (1) JP2026517735A (fr)
WO (1) WO2024226667A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201491643A1 (ru) * 2012-03-05 2015-02-27 Уэйн Стейт Юниверсити Идентификация мутаций канал-опсина-2 (chop2) и способы применения
US12459977B2 (en) * 2016-11-06 2025-11-04 Nanoscope Therapeutics, Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
EP3535282A4 (fr) * 2016-11-06 2020-04-08 Nanoscope Technologies LLC Modulation optogénétique par opsines à caractéristiques multiples pour la restauration de la vision et d'autres applications associées

Also Published As

Publication number Publication date
JP2026517735A (ja) 2026-06-02
WO2024226667A2 (fr) 2024-10-31
WO2024226667A3 (fr) 2025-01-09

Similar Documents

Publication Publication Date Title
AU2021245195B2 (en) Identification of Channelopsin-2 (Chop2) mutations and methods of use
JP6549559B2 (ja) 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
US20240165198A1 (en) Optogenetic visual restoration using chrimson
JP7046390B2 (ja) 細胞および組織に対する外来性分子のナノ強化型光学送達
JP2006517807A (ja) 中枢神経系の損傷の治療方法
JP2019194228A (ja) 疼痛を制御するための組成物及び方法
JP2016522794A (ja) 行動状態の光遺伝学的制御方法
KR20140039281A (ko) 감광성 키메라 gpcr 단백질
Nikonov et al. Restoration of vision and retinal responses after adeno-associated virus–mediated optogenetic therapy in blind dogs
Batabyal et al. Multi-characteristic opsin therapy to functionalize retina, attenuate retinal degeneration, and restore vision in mouse models of retinitis pigmentosa
US11180537B2 (en) Optogenetic modulation by Multi-Characteristic Opsins for vision restoration and other applications
US12459977B2 (en) Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
WO2024226667A2 (fr) Modulation optogénétique par opsines à caractéristiques multiples pour la restauration de la vision et d'autres applications associées

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251124

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)